12 September 2024
Assura plc
Scrip Calculation Price
Assura plc ("the Company") announces, in accordance with the terms and conditions of the Company's Scrip Dividend Scheme ("the Scheme"), that the Scrip Calculation Price in respect of the quarterly interim dividend proposed to be paid on 9 October 2024, is 40.78 pence. This is the average closing mid-market price of an ordinary share in the Company for the five dealing days commencing with, and including, the ex-dividend date of 5 September 2024.
If you wish to receive this quarterly interim dividend in cash, you do not need to take any action.
If you wish to participate in the Scheme and receive New Shares instead of your cash dividend, you should complete a Mandate, as follows:
· If you hold your Ordinary Shares in certificated form, and if you have not already done so, you should complete the Mandate Form (which is available to download from Assura's website www.assuraplc.com) in accordance with the instructions printed thereon and return it to Link Group at Central Square, 29 Wellington Street, Leeds, LS1 4DL by no later than 4.30 p.m. (London time) on 27 September 2024. The Mandate Form will remain in force for any future dividends in respect of which a Scrip Dividend Alternative is offered, until such time as the Mandate Form is cancelled.
· If you hold your Ordinary Shares in uncertificated form via the CREST System, you can only elect to receive dividends in the form of New Shares by submitting a CREST Dividend Election Input Message via the CREST System. Evergreen elections will not be permitted. This means that if you wish to receive New Shares instead of cash as a matter of routine whenever a Scrip Dividend Alternative is offered, you must complete and submit a CREST Dividend Election Input Message on each occasion, otherwise you will receive the relevant dividend in cash.
If you have any questions about the Scheme or how it operates, you can contact our Registrar, Link Group, at the address above or by telephone on 0371 664 0321. Lines are open between 9.00am and 5.30pm Monday to Friday, excluding public holidays.
Based upon the above Scrip Calculation Price, if all eligible Shareholders were to elect to take up their full entitlement to New Shares in respect of this quarterly interim dividend, approximately 66,669,258 New Shares would be issued. This would represent approximately 2.1 per cent. of the Company's issued share capital as at today's date. The total cash cost of this quarterly interim dividend if no Shareholders were to elect to take up their entitlement (and therefore no New Shares were to be issued) would be approximately £27.2 million.
Words and expressions defined in the circular dated 9 December 2015 in relation to the Scheme bear the same meanings in this announcement.
This interim dividend will be paid as 100% Property Income Distribution ("PID"). Forms to register for gross PIDs are available on the Company's website. Please click here for PID Forms.
- Ends -
For more information, please contact:
Assura plc |
Tel: 0161 515 2043 |
FGS Global Gordon Simpson |
Tel: 0207 251 3801 |
Notes to Editors
Assura plc is the UK's leading specialist healthcare property investor and developer. Assura enables better health outcomes through its portfolio of more than 600 healthcare buildings, from which over six million patients are served.
A UK REIT based in Altrincham, Assura is a constituent of the FTSE 250 and the EPRA* indices. As at 31 March 2024, Assura's portfolio was valued at £2.7 billion and has a strong track record of growing financial returns and dividends for shareholders.
At Assura we BUILD for health and as the first FTSE 250 certified B Corp we are committed to keeping ESG at the heart of our strategy, creating Healthy Environments (E) and Healthy Communities (S) and maintaining a Healthy Business (G).
Further information is available at www.assuraplc.com
*EPRA is a registered trademark of the European Public Real Estate Association.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.